Literature DB >> 1655490

Interactions of calmodulin antagonists with calcium antagonists binding sites.

P Schaeffer1, C Lugnier, J C Stoclet.   

Abstract

Calmodulin antagonists have calcium entry blocking properties. In order to quantitatively investigate the interactions of these drugs with calcium channels, their effect on [3H]nitrendipine and [3H]d-cis-diltiazem binding to rat cerebral cortex membrane preparations was compared to their inhibitory effect on the activation of cyclic nucleotide phosphodiesterase by calmodulin. The potency of most antagonists to inhibit [3H]nitrendipine binding was correlated with their calmodulin inhibitory potency. However, bepridil (K0.5 = 280 nM), chlorpromazine (K0.5 = 3 microM), triflupromazine (K0.5 = 1.5 microM), imipramine (K0.5 = 3 microM) and propranolol (K0.5 = 14 microM) were much more active on [3H]d-cis-diltiazem binding than on either [3H]nitrendipine binding or calmodulin, suggesting that these compounds bind to higher affinity sites on the calcium antagonist target protein. Moreover, the potencies of these compounds to compete with [3H]d-cis-diltiazem and to inhibit calcium-induced contractions in depolarized smooth muscle were correlated (R = 0.76, p less than 0.02). These data suggest that low concentrations of these hydrophobic drugs which have calcium and calmodulin antagonistic properties inhibit smooth muscle contraction through calcium entry blockade, not calmodulin antagonism.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1655490     DOI: 10.1016/0922-4106(91)90117-z

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Short- and long-term inhibition of cardiac inward-rectifier potassium channel current by an antiarrhythmic drug bepridil.

Authors:  Fangfang Ma; Hiroki Takanari; Kimiko Masuda; Masaki Morishima; Katsushige Ono
Journal:  Heart Vessels       Date:  2015-10-26       Impact factor: 2.037

2.  Bepridil up-regulates cardiac Na+ channels as a long-term effect by blunting proteasome signals through inhibition of calmodulin activity.

Authors:  L Kang; M Q Zheng; M Morishima; Y Wang; T Kaku; K Ono
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.